NASDAQ$OVID

Ovid Therapeutics Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

OVID Q4 2024 — $196.0M revenue, 0.20 EPS

Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of oper. Ovid Therapeutics Inc reported Q4 2024 results. Diluted EPS came in at $0.20. Net income of $37.0M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $196.0M.
  • Diluted EPS: $0.20.
  • Net income: $37.0M.
  • Operating income: $13K.

Headline financials

Total Revenue

$173K

Previous: $142K+22.2%
EPS (adj)

-$0.13

Previous: -$0.22+40.9%
Capital Expenditures

$4K

Previous: $13.7K-70.8%
Free Cash Flow

-$15M

No prior period
Net Income

-$14M

Previous: -$15.3M+8.6%
Operating Income

-$13.2M

Previous: -$18.2M+27.3%
Gross Profit

$4K

No prior period
R&D Expense

$7.75M

Previous: $10.6M-27.2%

Revenue & EPS history

Ovid Therapeutics · Revenue · Quarterly

$173K

Q4 2024+22.2%vs Q4 2023
Beat estimate in 9 of 11 quarters(82%)
ActualEstimate

Revenue by segment

Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020

  • License and other revenue
    $5.7M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-0.5%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+3.6%

Avg return

30 days after

43%

15 / 35 earnings

Positive

+19.5%

Q2 2024

Best reaction

-26.9%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.9%-5.7%
Q4 2025+14.4%+26.9%+44.8%
Q3 2025-2.2%-3.7%+21.5%
Q1 2025-0.7%-6.2%-8.2%
Q4 2024+0.1%-11.4%-48.0%
Q2 2024+19.5%+33.7%+31.4%
Q1 2024+9.9%+4.3%+6.0%
Q4 2023-7.3%-11.0%+2.5%
Q3 2023-7.9%-4.8%-9.5%
Q2 2023-1.8%-0.6%+6.6%
Q1 2023-5.2%-2.5%+0.1%
Q4 2022+4.0%+13.0%+46.0%
Q3 2022+2.1%+11.1%+26.4%
Q2 2022+0.5%+2.3%-1.4%
Q1 2022-12.1%-22.3%-30.5%
Q4 2021-3.4%+0.3%+0.3%
Q3 2021-2.8%+0.8%-9.7%
Q2 2021-9.4%-13.1%-14.4%
Q1 2021+2.3%+6.9%+28.4%
Q4 2020+4.4%+9.0%-6.1%
Q3 2020+18.9%+19.1%-49.6%
Q2 2020-2.4%+4.3%-20.4%
Q1 2020-0.3%+10.6%+43.7%
Q4 2019-26.9%-31.5%-7.8%
Q3 2019-1.5%-6.5%+54.2%
Q2 2019-2.1%-5.2%+11.9%
Q1 2019-14.0%-20.1%-24.8%
Q4 2018-2.0%+1.0%-6.1%
Q3 2018-8.0%-7.9%-39.1%
Q2 2018+2.3%+8.8%-0.2%
Q1 2018+4.8%-1.9%-9.5%
Q4 2017-13.1%-11.4%+35.7%
Q3 2017+15.2%+20.4%+49.7%
Q2 2017-1.6%+2.8%+28.0%
Q1 2017+5.3%+0.4%-29.7%
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro